GLP-1 Drug Heart Benefits in People Without Diabetes: What the Evidence Shows | Research

The takeaway

Review of cardiovascular benefits of GLP-1 drugs in non-diabetic populations shows significant heart protection extending beyond diabetes, primarily through the SELECT trial evidence.

20% fewer heart events
Semaglutide reduced cardiovascular events by 20% in obese people WITHOUT diabetes in the landmark SELECT trial

What the researchers found

GLP-1 drugs provide significant cardiovascular protection in non-diabetic populations, primarily evidenced by the SELECT trial showing 20% cardiovascular event reduction with semaglutide.

Why it matters

Cardiovascular disease is the leading cause of death globally. Proving GLP-1 drugs protect hearts even without diabetes dramatically expands the population that could benefit.

The numbers in context

8 eligible studies identified from 4 databases. Population includes T2DM patients with established ASCVD, CKD, or heart failure.

How the study worked

Review of cardiovascular outcome data for GLP-1 drugs in non-diabetic populations, including SELECT trial results and mechanistic evidence.

Who was studied

Adults with T2DM and established ASCVD, CKD, or heart failure across 8 studies

What this study cannot tell us

SELECT focused on semaglutide — cardiovascular benefit of other GLP-1 drugs in non-diabetics is extrapolated. BMI threshold for cardiovascular benefit not precisely defined.

How to read the evidence

Strong evidence: based on the SELECT randomized outcome trial with over 17,000 participants.

When this study was published

Published in 2025. Incorporates SELECT trial results establishing GLP-1 cardiovascular benefit in non-diabetics.

The bigger picture

The SELECT trial is a landmark in cardiovascular medicine — proving that treating obesity with GLP-1 drugs prevents heart attacks and strokes independently of diabetes. This repositions GLP-1 drugs from diabetes medications to cardiovascular protectors for the broader obese population.

Questions still open

Should all obese patients receive GLP-1 drugs for cardiovascular protection?
Do the cardiovascular benefits extend to overweight (not obese) non-diabetic patients?
How does GLP-1 cardiovascular protection compare to statin therapy in non-diabetics?

Common questions

Do I need diabetes to benefit from GLP-1 drugs for my heart?

No. The SELECT trial proved semaglutide reduces heart attacks and strokes by 20% in obese people without diabetes. GLP-1 drugs are now cardiovascular medicines, not just diabetes drugs.

Should I take semaglutide just for heart protection?

If you have obesity plus cardiovascular disease or high cardiovascular risk, the SELECT trial supports semaglutide for heart protection even without diabetes. Discuss with your cardiologist whether the benefits outweigh costs and potential side effects for your specific situation.

Read the original research

Cardiovascular Benefits of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Type 2 Diabetes Mellitus With Atherosclerotic Cardiovascular Disease: A Systematic Review of Randomized Controlled Trials.

Cureus, 17(8), e89514

View on PubMed ↗Publisher’s paper ↗

Citation

Ahmad, Maria; Sikandar, Ayesha; Aziz, Abdul; Bachar Al Sumodi, Wisam; Hans, Aakash; Usman, Muhammad. (2025). Cardiovascular Benefits of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Type 2 Diabetes Mellitus With Atherosclerotic Cardiovascular Disease: A Systematic Review of Randomized Controlled Trials.. Cureus, 17(8), e89514. https://doi.org/10.7759/cureus.89514